Eisai

Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Fierce Biotech
Mon, 02/14/22 - 12:05 pm
Hemavant
Roivant Sciences
Eisai
MDS
RVT-2001
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Mon, 01/3/22 - 10:45 pm
Biogen
Eisai
lecanemab
Alzheimer's disease
fast track
FDA
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Tue, 12/28/21 - 10:55 am
Biogen
Eisai
lecanemab
FDA
Aduhelm
fast track
Alzheimer's disease
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Wed, 12/22/21 - 11:06 am
Biogen
Eisai
Aduhelm
Japan
Alzheimer's disease
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
BioSpace
Thu, 11/11/21 - 10:55 am
Eisai
Biogen
lecanemab
Alzheimer's disease
clinical trials
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Pharmaforum
Wed, 10/20/21 - 10:08 am
Altoida
Eisai
clinical trials
augmented reality
Alzheimer's disease
Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval
Endpoints
Tue, 09/28/21 - 12:07 am
Biogen
Aduhelm
Eisai
Alzheimer's disease
FDA
lecanemab
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
Mon, 08/23/21 - 11:10 am
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Endpoints
Wed, 08/4/21 - 10:55 am
Biogen
Eisai
FDA
Alzheimer's disease
BAN2401
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Thu, 07/15/21 - 10:45 am
Biogen
Eisai
Alzheimer's disease
lecanemab
BAN2401
Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Pharmaceutical Business Review
Thu, 06/24/21 - 10:56 am
Eisai
Biogen
FDA
lecanemab
breakthrough status
Alzheimer's disease
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Fierce Biotech
Fri, 06/18/21 - 10:11 am
Bristol Myers Squibb
antibody-drug conjugate
MORAb-202
Eisai
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Reuters
Thu, 06/17/21 - 10:56 pm
Bristol Myers Squibb
Eisai
drug development
cancer

Pages